Proteasome inhibition in maintenance therapy

Where does proteasome inhibition fit in the maintenance treatment paradigm?

Professor Graham Jackson and Professor Meletios Dimopoulos discuss the influence of continuous proteasome inhibitor treatment as a maintenance strategy in newly diagnosed multiple myeloma and the latest evidence from clinical trials in this treatment landscape.

Interview following a Takeda symposium. The views expressed in the video are those of the speakers.

UK/NP/1806/0035ba - August 2018

You are now leaving the Myeloma Hub

This link opens another website that is not under the review or control of Takeda UK Ltd and, as such, the company does not endorse the content, its accuracy, or any practices or standards contained within it. Please confirm you wish to continue.